The loss of
NPC1 protein function is the predominant cause of Niemann-Pick type C1 disease (NP-C1), a systemic and
neurodegenerative disorder characterized by late-endosomal/lysosomal accumulation of
cholesterol and other
lipids. Limited evidence from post-mortem human tissues, an Npc1(-/-) mouse model, and cell culture studies also suggest failure of
metal homeostasis in NP-C1. To investigate these findings, we performed a comprehensive transition
metal analysis of cerebrospinal fluid (CSF), plasma and tissue samples from human NP-C1 patients and an Npc1(-/-) mouse model. NPC1 deficiency in the Npc1(-/-) mouse model resulted in a perturbation of transition
metal homeostasis in the plasma and key organs (brain, liver, spleen, heart, lungs, and kidneys). Analysis of human patient CSF, plasma and post-mortem brain tissues also indicated disrupted
metal homeostasis. There was a disparity in the direction of
metal changes between the human and the Npc1(-/-) mouse samples, which may reflect species-specific
metal metabolism. Nevertheless, common to both species is brain
zinc accumulation. Furthermore, treatment with the
glucosylceramide synthase inhibitor
miglustat, the only
drug shown in a controlled clinical trial to have some efficacy for NP-C1, did not correct the alterations in CSF and plasma transition
metal and
ceruloplasmin (CP) metabolism in NP-C1 patients. These findings highlight the importance of NPC1 function in
metal homeostasis, and indicate that
metal-targeting
therapy may be of value as a treatment for NP-C.